A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

Table 5 Genetic testing costs for genes as per Yu et al. [4]

CPT code	Explanation	Multiplier	NLA	Total NLA
83891	DNA Isolation	1	$5.7	$5.7
83900	Amplification of patient nucleic acid, multiplex, first two nucleic sequences	1	$47.8	$47.8
83901	Amplification of patient nucleic acid, multiplex, each additional acid sequence	10	$23.7	$237
83892	Digestion of amplified DNA with restriction endonuclease enzyme, each	2	$5.7	$11.4
83914	Mutation identification by enzymatic ligation or primer extension, single segment, each segment [e.g. oligonucleotide ligation assay (OLA), single base chain extension (SBCE), or allele-specific primer extension (ASPE)]	15	$23.7	$356
83912	Interpretation and report	1	$5.7	$5.7
83896	Nucleic acid probe, each	15	$5.7	$85
83903	Molecular diagnostics; mutation scanning by physical properties, single segment, each	15	$23.7	$356
83908	Molecular diagnostics; signal amplification of patient nucleic acid, each nucleic acid sequence	15	$23.7	$356
Cost per patient tested				$1461
Adjusted for a genetic testing age of 65 years and ranibizumab. Total treatment age of 75 years (compounded at 3 % annually)				$1906
Including the $299 incremental yearly ophthalmic examination and optical coherence. Total tomogram in the 20 % of patients with a high-risk genetic score [4]				$2205

CPT Current Procedural Terminology, published by the American Medical Association, NLA National Limitation Amount, all cost in 2012 US nominal dollars

ISSN: 2056-9920